Advances in the Diagnosis and Treatment of Guillain-Barré Syndrome: Insights from 2023

• DOI: https://doi.org/10.22533/at.ed.1594582426067

• Palavras-chave: Guillain-Barré syndrome, immunotherapy, diagnosis, treatment.

• Keywords: Guillain-Barré syndrome, immunotherapy, diagnosis, treatment.

• Abstract:

  Objective: Evaluate and synthesize the most recent advances in diagnostic criteria, biomarkers, treatments, rehabilitation strategies, and long-term follow-up for Guillain-Barré Syndrome, with the aim of determining the impact of these updates on the prognosis and recovery rates of patients. patients affected by this condition. Methods: Narrative bibliographic review study, using the Pubmed database. A search was carried out using the research strategy: (Guillain Barre Syndrome) AND (Management) AND (Diagnosis). Initially, 263 articles were found, of which 20 were selected after applying inclusion and exclusion criteria. Review: The advances in the diagnosis and treatment of GBS, highlight the importance of specific biomarkers, such as metallo-proteinases (MMP-2), vascular endothelial growth factor (VEGF), sphingomyelin (SM), pre-albumin, fibrinogen and haptoglobin and in analysis identification of unfavorable lipid profiles in early diagnosis. Furthermore, traditional therapies, such as Human Immune Globulin (IVIG) and Plasmapheresis (PE), present efficacy in treatment, but also the associated risks, also highlighting the need for an abcustom order and the lack of other available alternatives.
  Final considerations: The importance of early diagnosis and treatment of Guillain Barré Syndrome (GBS) was highlighted, directly impacting the patient's prognosis and being able to avoid any permanent axonal injury in patients with severe conditions and risk factors. Highlighting the lack of research focused on understanding the pathological mechanisms of GBS, enabling the development of other therapies that could provide a better prognosis.